BENSALEM, Pa., Oct. 27, 2017 -- Law Offices of Howard G. Smith reminds investors of the October 27, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE:VSI) securities between March 1, 2017, and August 6, 2017, inclusive (the “Class Period”). Vitamin Shoppe investors have until October 27, 2017 to file a lead plaintiff motion.
Investors suffering losses on their Vitamin Shoppe investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].
The complaint filed in this class action alleges that during the Class Period, defendants failed to disclose that the Company’s retail segment was continuing to dramatically decline, as its ongoing “reinvention plan” unsuccessful. In addition, Vitamin Shoppe failed to recognize an impairment charge relating to the Company’s failed reinvention plan.
On May 10, 2017, Vitamin Shoppe released poor first quarter 2017 financial results and slashed the Company’s fiscal 2017 guidance by 45%, and still claimed the Vitamin Shoppe’s “reinvention plan” was still succeeding. On this news, the price of Vitamin Shoppe stock declined by one-third to close at $12.70 per share.
Then, on August 9, 2017, Vitamin Shoppe announced that it was taking a $168.1 million impairment charge relating to the Company’s retail segment, and that, as a result, Vitamin Shoppe would report a loss per share of $6.73. In addition, the Company dropped its fiscal 2017 earnings per share guidance altogether. On this news, Vitamin Shoppe’s common stock plunged again, falling $3.50 per share to close at $6.10 per share.
If you purchased shares of Vitamin Shoppe during the Class Period you may move the Court no later than October 27, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Anta Sports Expands Global Footprint With Strategic Puma Stake
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 



